임
임영애 Chief Executive Officer
C-suite F
Explore the full record of transactions filed by 임영애, Chief Executive Officer. Officer active across 2 companies, notably 케이엠제약. Cumulatively, 45 disclosures have been recorded. History available since 11 March 2026. The latest transaction was filed on 21 April 2026 (Purchase). Regulator: DART (FSS). All data is accessible without signup.
Declarations 45 total
● Executives · 1 Jun 2026 (filed)
● Executives · 1 Jun 2026 (filed)
● Executives · 21 Apr 2026 (filed) · 케이엠제약 11,300 shares DART:20260421000240 Ideal exit: 16 Jan 2027 (T+270) ● 상무이사 · Executives · 13 Apr 2026 · 케이엠제약 1,300 shares @ ₩535.0692 0.0000% mcap 100.0% of flow Share DART:20260420000241 Ideal exit: 8 Jan 2027 (T+270) ● Executives · 9 Apr 2026 (filed) · 케이엠제약 23,711 shares DART:20260409002021 Ideal exit: 4 Jan 2027 (T+270) ● 회장 · Executives · 25 Mar 2026 · 케이엠제약 600 shares @ ₩465.00 0.0000% mcap 1.8% of flow Share DART:20260409001985 Ideal exit: 20 Dec 2026 (T+270) ● 대표이사 · Executives · 17 Mar 2026 · 케이엠제약 26,863 shares @ ₩410.0109 0.0000% mcap 100.0% of flow Share DART:20260324000665 Ideal exit: 12 Dec 2026 (T+270) ● Executives · 24 Mar 2026 (filed) · 케이엠제약 26,863 shares DART:20260324000881 Ideal exit: 19 Dec 2026 (T+270) ● Executives · 23 Mar 2026 (filed)
● 대표이사 · Executives · 6 Mar 2026 · 케이엠제약 38,485 shares @ ₩391.2617 0.0001% mcap 98.2% of flow Share DART:20260311003196 Ideal exit: 1 Dec 2026 (T+270) ● Executives · 11 Mar 2026 (filed) · 케이엠제약 38,485 shares DART:20260311003218 Ideal exit: 6 Dec 2026 (T+270) ● Executives · 3 Mar 2026 (filed) · 케이엠제약 24,821 shares DART:20260303001597 Ideal exit: 28 Nov 2026 (T+270) ● 대표이사 · Executives · 3 Mar 2026 (filed) · 케이엠제약 24,821 shares Share DART:20260303001554 Ideal exit: 28 Nov 2026 (T+270) ● Executives · 9 Feb 2026 (filed) · 케이엠제약 5,600 shares DART:20260209000516 Ideal exit: 6 Nov 2026 (T+270) ● 상무이사 · Executives · 2 Feb 2026 (filed) · 케이엠제약 Share DART:20260202000162 Ideal exit: 30 Oct 2026 (T+270) ● Executives · 2 Feb 2026 (filed) · 케이엠제약 6,773 shares DART:20260202000282 Ideal exit: 30 Oct 2026 (T+270) ● Executives · 12 Jan 2026 (filed) · 케이엠제약 ● Executives · 8 Dec 2025 (filed) · 케이엠제약 ● Executives · 8 Jul 2025 (filed)
● Executives · 8 Apr 2025 (filed)
● Executives · 6 Jan 2025 (filed)
● Executives · 6 Dec 2024 (filed) · 케이엠제약 ● Executives · 8 Oct 2024 (filed) · 케이엠제약 ● Executives · 10 Jul 2024 (filed) · 케이엠제약 ● Executives · 1 Jul 2024 (filed) · 케이엠제약 25 of 45 declarations
Load more (20 remaining) About 임영애 Im Young-ae is the Executive Director at KM Pharmaceutical, where he plays a key role in managing operations and strategic development. With extensive experience in the pharmaceutical sector, he oversees projects and ensures process efficiency. His leadership is crucial for the success of KM Pharmaceutical.